



**Central Depository Company
of Pakistan Limited**

Head Office: CDC House, 99-B,
Block 'B', S.M.C.H.S.,
Main Shahra-e-Faisal,
Karachi-74400

Ref. No. CDC/C/N/02/2022

March 07, 2022

Notification No. 02 of 2022

Sub: Amendments in the Schedule of Fees & Deposits

To,
The General Public,

This is to bring to the notice of general public that the Board of Directors of CDC in its drive to rationalize fees & schedule has further reduced the maximum ceiling on Consolidation and/or Sub-Division of Securities. The proposed maximum ceiling has now been limited to Rs.1 million as against the current ceiling of Rs.2 million. This initiative will promote ease of doing business and facilitation for the Issuers of the capital market.

Accordingly, Schedule of Fees and Deposits approved by the CDC Board are also enclosed herewith. As required under Section 51(2) of the Securities Act, 2015 (III of 2015), CDC has placed such amendments for soliciting public comments which may be submitted, in the manner as suggest in the "Guidelines for Submission of Comments", within 7 days of this Notification i.e. by **Monday, March 14, 2022**.

Regards,

Hammad Ali Faisal
Chief Compliance Officer

The Director/ HOD (PRDD-SMD)
Securities and Exchange Commission of Pakistan
Islamabad

The Chief Executive Officer
Pakistan Stock Exchange Limited
Karachi

The Chief Executive Officer
National Clearing Company of Pakistan Limited
Karachi

All CDS Elements

THE CENTRAL DEPOSITORY COMPANY OF PAKISTAN LIMITED

UPDATED: MARCH 2022

FEES AND DEPOSITS SCHEDULE @

SCHEDULE OF FEES						
S. No.	NAME	RATE	BASIS	LEVIED ON	COLLECTION	
					WHEN	MODE
12.	Fee on Consolidation and/or Sub-Division of Securities	0.16%	Market value***** (Note 8)	Issuer	With application	P.O./Draft/Cheque

Notes:

8| To be levied on Issuer consolidating or sub-dividing its securities. This fee shall not exceed ~~Rs. 2~~ Rs. 1 million.

UPDATED: MARCH 2022

Guidelines for Submission of Comments

1. CDC invites the interested parties to provide their comments and views, with specific reference to the subject matter of the proposed amendments to CDC Regulations notified via notices, through any of the following modes.

Email	comments@cdcpak.com
Mail	The Chief Compliance Officer, Central Depository Company of Pakistan Limited CDC House, 99-B, Block 'B', S.M.C.H.S., Main Shahra-e-Faisal, Karachi-74400, Pakistan

2. At the time of submission of comments, respondent is advised to provide the information, as per **Table-A** below, so that CDC may contact him/her for clarification or deliberation on the comments, if needed. Anonymous responses may be disregarded by CDC.

Table A

To Be Filed By The Respondent	
Name of respondent	
Account No.	
Name of company (if applicable)	
Designation (if applicable)	
Contact Number	
Email Address	

3. The respondent may request confidential treatment for his/ her identity and all or any part of comments due to their proprietary, confidential or commercial nature, by clearly marking the information in **Table-B** below:

Table B

Disclosure of Identity and Comments

<p>Please check the box(es) if you wish to be remain confidential:</p> <p><input type="checkbox"/> I wish to have my identity remain confidential.</p> <p><input type="checkbox"/> I wish to keep all or any part of my comments confidential.</p>
--

If respondent wishes to keep any part(s) of comments confidential, then he/she is required to clearly specify such part(s) of comments.

4. To ensure quality and promote transparency, CDC will publish the relevant comments of respondents and its management's response thereon in the form of a Response Paper on its website, within a reasonable timeframe, after close of public consultation session, unless the respondent has made a confidentiality request.
5. Any policy or rule amendment may be subject to regulatory concurrence. For this purpose, respondents should note that notwithstanding any confidentiality request, CDC will share all their response(s) with the Securities and Exchange Commission of Pakistan (Apex Regulator).
6. By submitting comments, respondents are deemed to have consented to the collection, use and disclosure of data that is provided to CDC, unless respondents wish to have their identity or comments remain confidential.